Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA6 | P23280 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL666959 | 0.94 | KDM4E (0.59) | KDM4EALDH1A1HPGDCA12CA9 | |
| Salicylic Acid SCHEMBL3468302 | 0.89 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDCA12CA9 | |
| Salicylic Acid SCHEMBL17710452 | 0.87 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDSMN1; SMN2LMNA | |
| Phthalic Acid SCHEMBL5048545 | 0.85 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGDCA2SMN1; SMN2 | |
| Cinnamic Acid SCHEMBL669104 | 0.83 | MAPT (0.48) | KDM4EALDH1A1HPGDSMN1; SMN2LMNA | |
| Tetrabuthylammonium SCHEMBL11218875 | 0.83 | KDM4E (0.53) | KDM4EALDH1A1HPGDCA12CA9 | |
| Tributylmethylammonium SCHEMBL668411 | 0.82 | KDM4E (0.51) | KDM4EALDH1A1HPGDCA12CA9 | |
| Salicylic Acid SCHEMBL8621859 | 0.81 | ALDH1A1 (0.72) | KDM4EALDH1A1HPGDCA12CA9 | |
| Salicylic Acid SCHEMBL294304 | 0.81 | ALDH1A1 (0.72) | KDM4EALDH1A1HPGDCA12CA9 | |
| Salicylic Acid SCHEMBL28753449 | 0.81 | ALDH1A1 (0.44) | KDM4EALDH1A1HPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278134-B2 | Dual functioning ionic liquids and salts thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2016-03-08 | — | — | US | disclosed |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010078300-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | SLC6A6, SLC10A2, CLK2 | KDM4E 4730/4885ALDH1A1 3146/4885HPGD 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.